Carbetocin Versus Oxytocin for Prevention of Postcesarean Hemorrhage in Pregnancy With High Risk for PPH
NCT ID: NCT04089176
Last Updated: 2019-09-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
120 participants
INTERVENTIONAL
2019-02-01
2019-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Carbetocin vs. Oxytocin at Elective Cesarean Section
NCT03168698
Carbetocin Versus Oxytocin and Ergometrine for the Prevention of Postpartum Hemorrhage
NCT03578263
Carbetocin and Oxytocin in Elective Caesarean Section With High Risk of Postpartum Hemorrhage
NCT02391636
Carbetocin Versus Ergometrin in the Prevention of Postpartum Hemorrhage
NCT04300452
Oxytocin i.m./i.v. Versus Carbetocin i.v. in Elective Cesarean Sections
NCT03651882
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
protocal A
Carbetocin versus placebo
Carbetocin
carbetocin 100 mcg + RLS solution 10 ml injected directly into the vein over 2 min
oxytocin
oxytocin 20 IU diluted in 1000 ml of RLS solution administered intravenously at rate 120 ml/hr x 8 hr
protocal B
Oxytocin versus placebo
Carbetocin
carbetocin 100 mcg + RLS solution 10 ml injected directly into the vein over 2 min
oxytocin
oxytocin 20 IU diluted in 1000 ml of RLS solution administered intravenously at rate 120 ml/hr x 8 hr
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carbetocin
carbetocin 100 mcg + RLS solution 10 ml injected directly into the vein over 2 min
oxytocin
oxytocin 20 IU diluted in 1000 ml of RLS solution administered intravenously at rate 120 ml/hr x 8 hr
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* polyhydramnios
* fetal macrosomia
* previous cesarean section
* grand multiparity
* intramural myoma
* chorioamnionitis
* prolonged premature rupture of membrane
* augmentation of labour
Exclusion Criteria
* on anticoagulant
* placenta previa or placenta percreta
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Department of Medical Services Ministry of Public Health of Thailand
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rajavithi Hospital
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
T.Sopida
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.